Association of Continuous Glucose Monitoring-Derived Glycemia Risk Index With Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus: A Cross-sectional Study

Overview

Journal J Diabetes Sci Technol

Specialty Endocrinology

Date 2024 Oct 14

PMID 39397773

Authors

Ji Eun Jun

You-Bin Lee

Jae Hyeon Kim

Affiliations

Soon will be listed here.

Abstract

Background: The glycemia risk index (GRI) is a new composite continuous glucose monitoring (CGM) metric for weighted hypoglycemia and hyperglycemia. We evaluated the association between the GRI and cardiovascular autonomic neuropathy (CAN) and compared the effects of the GRI and conventional CGM metrics on CAN.

Methods: For this cross-sectional study, three-month CGM data were retrospectively analyzed before autonomic function tests were performed in 165 patients with type 1 diabetes. CAN was defined as at least two abnormal results of parasympathetic tests according to an age-specific reference.

Results: The overall prevalence of CAN was 17.1%. Patients with CAN had significantly higher GRI scores, target above range (TAR), coefficient of variation (CV), and standard deviation (SD) but significantly lower time in range (TIR) than those without CAN. The prevalence of CAN increased across higher GRI zones ( for trend <.001). A multivariate logistic regression analysis, adjusted for covariates such as HbA1c, demonstrated that the odds ratio (OR) of CAN was 9.05 (95% confidence interval [CI]: 2.21-36.96, = .002) per 1-SD increase in the GRI. TIR and CV were also significantly associated with CAN in the multivariate model. The area under the curve of GRI for the prediction of CAN (0.85, 95% CI: 0.76-0.94) was superior to that of TIR (0.80, 95% CI: 0.71-0.89, for comparison = .046) or CV (0.71, 95% CI: 0.57-0.84, for comparison = .049).

Conclusions: The GRI is significantly associated with CAN in patients with type 1 diabetes and may be a better CGM metric than TIR for predicting CAN.

References

El Malahi A, Van Elsen M, Charleer S, Dirinck E, Ledeganck K, Keymeulen B . Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2021; 107(2):e570-e581. DOI: 10.1210/clinem/dgab688. View

Yapanis M, James S, Craig M, ONeal D, Ekinci E . Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring. J Clin Endocrinol Metab. 2022; 107(6):e2221-e2236. PMC: 9113815. DOI: 10.1210/clinem/dgac034. View

Ewing D, Martyn C, Young R, CLARKE B . The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985; 8(5):491-8. DOI: 10.2337/diacare.8.5.491. View

Pafili K, Trypsianis G, Papazoglou D, Maltezos E, Papanas N . Simplified Diagnosis of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes Using Ewing's Battery. Rev Diabet Stud. 2015; 12(1-2):213-9. PMC: 5397991. DOI: 10.1900/RDS.2015.12.213. View

Jun J, Lee S, Lee Y, Ahn J, Kim G, Jin S . Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients. Cardiovasc Diabetol. 2017; 16(1):127. PMC: 5635541. DOI: 10.1186/s12933-017-0619-2. View

Danne T, Nimri R, Battelino T, Bergenstal R, Close K, DeVries J . International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017; 40(12):1631-1640. PMC: 6467165. DOI: 10.2337/dc17-1600. View

Chowdhury M, Nevitt S, Eleftheriadou A, Kanagala P, Esa H, Cuthbertson D . Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis. BMJ Open Diabetes Res Care. 2021; 9(2). PMC: 8719152. DOI: 10.1136/bmjdrc-2021-002480. View

Naaman S, Mizrak H, Lind N, Laursen J, Kufaishi H, Christensen M . Cardiovascular Autonomic Neuropathy Is Associated With Increased Glucose Variability in People With Type 1 Diabetes. Diabetes Care. 2022; 45(10):2461-2465. DOI: 10.2337/dc22-0117. View

Kim M, Kim G, Park J, Choi M, Jun J, Lee Y . The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes. Diabetes Technol Ther. 2021; 23(6):434-442. DOI: 10.1089/dia.2020.0599. View

10.

Shah V, Sakamoto C, Pyle L . Optimal Sampling Duration for Continuous Glucose Monitoring for the Estimation of Glycemia Risk Index. Diabetes Technol Ther. 2022; 25(2):140-142. DOI: 10.1089/dia.2022.0401. View

11.

Reyes del Paso G, Langewitz W, Mulder L, van Roon A, Duschek S . The utility of low frequency heart rate variability as an index of sympathetic cardiac tone: a review with emphasis on a reanalysis of previous studies. Psychophysiology. 2013; 50(5):477-87. DOI: 10.1111/psyp.12027. View

12.

Beck R, Bergenstal R, Riddlesworth T, Kollman C, Li Z, Brown A . Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2018; 42(3):400-405. PMC: 6905478. DOI: 10.2337/dc18-1444. View

13.

Pop-Busui R . Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care. 2010; 33(2):434-41. PMC: 2809298. DOI: 10.2337/dc09-1294. View

14.

Jaiswal M, McKeon K, Comment N, Henderson J, Swanson S, Plunkett C . Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2014; 37(9):2616-21. PMC: 4140160. DOI: 10.2337/dc14-0445. View

15.

Serhiyenko V, Serhiyenko A . Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018; 9(1):1-24. PMC: 5763036. DOI: 10.4239/wjd.v9.i1.1. View

16.

Duque A, Mediano M, De Lorenzo A, Rodrigues Jr L . Cardiovascular autonomic neuropathy in diabetes: Pathophysiology, clinical assessment and implications. World J Diabetes. 2021; 12(6):855-867. PMC: 8192252. DOI: 10.4239/wjd.v12.i6.855. View

17.

Jun J, Lee S, Lee Y, Ahn J, Kim G, Hur K . Continuous glucose monitoring defined glucose variability is associated with cardiovascular autonomic neuropathy in type 1 diabetes. Diabetes Metab Res Rev. 2018; 35(2):e3092. DOI: 10.1002/dmrr.3092. View

18.

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 6. Glycemic Targets: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S97-S110. PMC: 9810469. DOI: 10.2337/dc23-S006. View

19.

Lachin J, Genuth S, Nathan D, Zinman B, Rutledge B . Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes. 2008; 57(4):995-1001. DOI: 10.2337/db07-1618. View

20.

Raj R, Mishra R, Jha N, Joshi V, Correa R, Kern P . Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2022; 10(1). PMC: 8724710. DOI: 10.1136/bmjdrc-2021-002573. View